Personalis at AACR Annual Meeting: April 10-15, 2021 and May 17-21, 2021

Poster Presentations

Rachel Pyke

April 10 – 15, 2021 and May 17 – 21, 2021 

Poster # 399
Poster Title: Pan-cancer survey of HLA loss of heterozygosity using a robustly validated NGS-based machine learning algorithm 
Session Category: Clinical Research (Excluding Trials)
Session Title: Biomarkers Predictive of Therapeutic Benefit
Presenter: Rachel Marty Pyke, PhD

Charles Abbott

April 11 – 15, 2021 and May 17 – 21, 2021 

Poster # 555
Poster Title: Longitudinal exome-scale liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy
Session Category: Clinical Research (Excluding Trials)
Session Title: Liquid Biopsies: Circulating DNA
Presenter: Charles Abbott, PhD

Rachel Pyke

April 10 – 15, 2021 and May 17 – 21, 2021 

Poster # 1898
Poster Title: Accurate modeling of antigen processing and MHC peptide presentation using large-scale immunopeptidomes and a novel machine learning framework  
Session Category: Immunology 
Session Title: Tumor Antigenicity/Processing and Presentation 
Presenter: Rachel Marty Pyke, PhD

Fábio Navarro

April 10 – 15, 2021 and May 17 – 21, 2021

Poster # 2227
Poster Title: Pan-cancer shedding patterns of tumor circulating cell free DNA 
Session Category: Molecular and Cellular Biology / Genetics
Session Title: Genomic Profiling of Tumors
Presenter: Fábio Navarro, PhD

Eric Levy

April 10 – 15, 2021 and May 17 – 21, 2021

Poster # 2241
Poster Title: Profiling tumor-infiltrating immune cells using an augmented transcriptome  
Session Category: Molecular and Cellular Biology / Genetics
Session Title: Genomic Profiling of Tumors
Presenter: Eric Levy, PhD

AACR Product Demo

April 10 – 15, 2021 and May 17 – 21, 2021

Product Demo
Presentation Title: Advancing Biomarker Discovery: Enabling improved tumor immunogenomics through a comprehensive approach
Presenter: Travis Yates, PhD

This presentation will cover:

  • Predicting patient response to immunotherapies requires a robust and comprehensive approach to tumor immunogenomics.
  • By combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXT™ provides a broad view of the tumor and the immune-related components of the tumor microenvironment from a single, limited sample.
  • Combination of ImmunoID NeXT and our exome-wide liquid biopsy assay, NeXT Liquid Biopsy, allows for increased exploration of critical areas of tumor biology.